StockData
Spruce Biosciences, Inc. logo

Spruce Biosciences, Inc. (SPRB) stock

SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/30
$42.89−3.31 (-7.16%)

Close on Nov 12, 2026Market cap $123.27MP/E –Yield –

Spruce Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Spruce Biosciences's ebitda for the twelve months ending Sep 30, 2026 was -$61.95M. For fiscal 2025 it was -$36.49M. The highest annual figure on record is -$13.10M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$36.49M–
FY2024Dec 31, 2024-$56.11M–
FY2023Dec 31, 2023-$51.92M–
FY2022Dec 31, 2022-$47.21M–
FY2021Dec 31, 2021-$42.00M–
FY2020Dec 31, 2020-$29.38M–
FY2019Dec 31, 2019-$13.10M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$23.24M–
Q2 FY2026Jun 30, 2026-$15.88M–
Q1 FY2026Mar 31, 2026-$11.74M–
Q4 FY2025Dec 31, 2025-$11.10M–
Q3 FY2025Sep 30, 2025-$8.23M–
Q2 FY2025Jun 30, 2025-$2.69M–
Q1 FY2025Mar 31, 2025-$14.49M–
Q4 FY2024Dec 31, 2024-$24.07M–
Q3 FY2024Sep 30, 2024-$9.40M–
Q2 FY2024Jun 30, 2024-$10.02M–
Q1 FY2024Mar 31, 2024-$12.62M–
Q4 FY2023Dec 31, 2023-$11.15M–
Q3 FY2023Sep 30, 2023-$13.64M–
Q2 FY2023Jun 30, 2023-$13.95M–
Q1 FY2023Mar 31, 2023-$13.18M–
Q4 FY2022Dec 31, 2022-$12.09M–
Q3 FY2022Sep 30, 2022-$11.53M–
Q2 FY2022Jun 30, 2022-$11.88M–
Q1 FY2022Mar 31, 2022-$11.71M–
Q4 FY2021Dec 31, 2021-$9.12M–
Q3 FY2021Sep 30, 2021-$11.38M–
Q2 FY2021Jun 30, 2021-$11.70M–
Q1 FY2021Mar 31, 2021-$9.80M–
Q4 FY2020Dec 31, 2020-$8.33M–
Q3 FY2020Sep 30, 2020-$9.55M–
Q2 FY2020Jun 30, 2020-$6.37M–
Q1 FY2020Mar 31, 2020-$5.13M–
Q4 FY2019Dec 31, 2019-$3.13M–

More Spruce Biosciences figures

See a number that looks wrong?